Rekvina Laboratories FY26 Update: Revenue Commencement and Strategic Acquisition

Revenue from operations stood at Rs 1.27 crore for FY26; the acquisition of Radiant Parenterals was finalized for Rs 4.63 crore.

Reader Takeaway: Revenue has finally commenced, but widening losses and a negative net worth remain significant hurdles for shareholders.

What just happened

Rekvina Laboratories has officially moved past its zero-revenue phase, reporting Rs 1.27 crore in revenue for the fiscal year ended March 31, 2026. Simultaneously, the board has cleared the 100% acquisition of Radiant Parenterals Limited. This deal is being financed through a share swap arrangement involving the issuance of 46.27 lakh equity shares. The company also secured Rs 46 lakh in cash via a preferential allotment of 4.6 lakh shares.

Why this matters

This marks a structural pivot for the company. The acquisition is intended to expand the firm's operational capacity. However, the financial results show the company is still in a high-burn phase, with total expenses rising to Rs 1.52 crore, leading to a net loss of Rs 0.25 crore for the year.

Governance and Board Updates

Leadership changes are underway with the appointment of Mr. Prateek Jain and Mr. Jay Chintan Patel as Independent Directors. Concurrently, Company Secretary and Compliance Officer Mr. Deepak Khandelwal has resigned effective September 2, 2026.

Risks to watch

Investors should be cautious of the company’s negative net worth of Rs 1.23 crore. Additionally, auditors have flagged that the accounting system currently cannot provide a full breakdown of dues owed to MSMEs. Furthermore, the transmission of shares belonging to a late promoter is currently stalled due to regulatory lock-in requirements.

Context metrics

• Revenue (FY26): Rs 1.27 crore
• Net Loss (FY26): Rs 0.25 crore
• Authorized Capital: Increased from Rs 3.50 crore to Rs 6.00 crore.